Obermatt
See Similar Stocks →

Vetoquinol

PAR:VETO · FR0004186856
PharmaceuticalsMedium

360

76
EV / EBIT84
Price / Owner Earnings40
Owner Earnings Yield90
Dividend Yield57
Price/Sales86
EV / Gross Profit84
Price/Book79
Return on Capital83
Cash Return on Capital83
Return on Equity70
EBIT Margin73
Gross Profitability70
Cash Conversion59
Accruals43
Owner Earnings Margin75
Sales growth20
Profit Growth32
Long-Term EPS Growth41
Owner Earnings Growth58
Reinvestment85
Price momentum36
Debt load81
Refinancing86
Debt Payback100
Liquidity92
Analyst ratings40
Opinion Changes10
Price Target Upside29
Market mood53
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Vetoquinol clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryFrance
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeENXTPA
Founded1962
Employees973
Websitevetoquinol.com/fr
ISINFR0004186856
Last UpdateApr 2, 2026
Indices
CAC All (France)
Themes
LivestockPet CarePain ManagementNephrologyBiotechnologyMedicalVeterinary

Description

Analysis

Quality compounder

Vetoquinol SA earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is attractive. The owner-earnings multiple stands at 12.5×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
65
2023202420252026

All-time high

96

Jan 2024

All-time low

39

Jan 2025

Average rank

64

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
86
69
65
64
Price/Earnings
54
75
43
42
Price/Book
79
75
59
52
Dividend Yield
57
39
47
47
Value (overall)
85
79
61
56

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Vetoquinol with its peers
Virbac
PAR:VIRP
58
CountryFrance
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Krka
LJU:KRKG
63
CountrySlovenia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Sandoz
SWX:SDZ
18
CountrySwitzerland
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
GlaxoSmithKline Pharmaceuticals
NSI:GLAXO
53
CountryUK
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Euroapi
PAR:EAPI
37
CountryFrance
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Bayer
GER:BAYN
15
CountryGermany
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →